This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Training and Resources

Prescribing Information

KEYTRUDA® (pembrolizumab) in HNSCC

KEYTRUDA, as monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1

 

KEYTRUDA® monotherapy

 

Patient management

 

PD-L1 Testing and CPS Interpretation in HNSCC

 

Patient education and support materials

 

More information about KEYTRUDA® (pembrolizumab) in HNSCC

By clicking this link you will be taken to an MSD promotional website.

Supporting documentation

Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-OHN-00266 | Date of Preparation: December 2020